Warren Center for Neuroscience Drug Discovery

Craig Lindsley, the William K. Warren, Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry

Craig Lindsley named to Medicinal Chemistry Division of the American Chemical Society Hall of Fame

Jun. 15, 2021—Craig Lindsley, the William K. Warren, Jr. Chair in Medicine and director of Vanderbilt’s  Warren Center for Neuroscience Drug Discovery, will be inducted to the 2021 class of the Division of Medicinal Chemistry Hall of Fame.

array of test tubes with pipette dropping fluid into one

Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics

Feb. 25, 2021—A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes.

Jerri Rook is awarded the Alzheimer’s Drug Discovery Foundation’s prestigious Melvin R. Goodes prize

Nov. 2, 2020—Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research.

Warren Center for Neuroscience Drug Discovery names Craig Lindsley as director

Oct. 20, 2020—Craig Lindsley, the William K. Warren, Jr. Chair and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, effective Dec. 1, 2020.

illustration of identical pink brain laid out in a pattern

Turning Heads: The Vanderbilt Brain Institute has emerged as a hub of discovery as neuroscience’s influence expands

Aug. 5, 2020—The VBI recently marked its 20th anniversary, a span that has seen the institute’s wide-ranging missions—including administering the university’s Neuroscience Graduate Program, as well as postdoctoral training and community outreach—steadily coalesce under a single umbrella.

Committed to Memory: VU319 may hold the key to improving memory loss in Alzheimer’s patients

Jul. 23, 2020—VU319, an investigational drug product developed by Vanderbilt researchers, targets one of medicine’s most bedeviling challenges: improving memory loss in people with Alzheimer’s disease.

Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders

Jun. 16, 2020—Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia.

Leader in Vanderbilt drug discovery efforts, Craig Lindsley named interim editor-in-chief of ACS Pharmacology & Translational Science

Jun. 12, 2020—Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of biochemistry, chemistry and pharmacology, has been named interim editor-in-chief of the journal "ACS Pharmacology & Translational Science."

Vanderbilt receives $20 million from The William K. Warren Foundation to further treatments for brain disorders

May. 5, 2020—Vanderbilt University has received $20 million from The William K. Warren Foundation, located in Tulsa, Oklahoma, to establish the Warren Center for Neuroscience Drug Discovery to support pharmaceutical breakthroughs.